Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 | Infectious Diseases | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
World Health Organization. Coronavirus disease (COVID-19) pandemic. Accessed April 25, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2.
Centers for Disease Control and Prevention. COVID data tracker. Accessed April 25, 2021. https://covid.cdc.gov/covid-data-tracker/
3.
Sadoff  J, Gray  G, Vandebosch  A, et al; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544PubMed
4.
Pawlowski  C, Wagner  T, Puranik  A,  et al.  Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC).   eLife. 2020;9:e59209. doi:10.7554/eLife.59209 PubMedGoogle Scholar
5.
Pawlowski  C, Venkatakrishnan  AJ, Ramudu  E,  et al.  Pre-existing conditions are associated with COVID-19 patients’ hospitalization, despite confirmed clearance of SARS-CoV-2 virus.   EClinicalMedicine. 2021;34:100793. doi:10.1016/j.eclinm.2021.100793 PubMedGoogle Scholar
6.
Pawlowski  C, Lenehan  P, Puranik  A,  et al.  FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.   Med (N Y). 2021;2(8):979-992. doi:10.1016/j.medj.2021.06.007PubMedGoogle Scholar
7.
McMurry  R, Lenehan  P, Awasthi  S,  et al.  Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.   Med (N Y). 2021;2(8):965-978. doi:10.1016/j.medj.2021.06.006PubMedGoogle Scholar
8.
Pawlowski  C, Rincón-Hekking  J, Awasthi  S, et al. Cerebral venous sinus thrombosis is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state health system.  J Stroke Cerebrovasc Dis. 2021;16(1):105923. doi:10.1016/j.jstrokecerebrovasdis.2021.105923
9.
Austin  PC.  An introduction to propensity score methods for reducing the effects of confounding in observational studies.   Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786 PubMedGoogle ScholarCrossref
10.
Austin  PC. A comparison of 12 algorithms for matching on the propensity score.  Stat Med. 2014;33(6):1057-1069. doi:10.1002/sim.6004PubMed
11.
Sahai  H, Khurshid  A.  Statistics in Epidemiology: Methods, Techniques and Applications. CRC Press; 1995.
12.
Centers for Disease Control and Prevention. United States COVID-19 cases and deaths by state over time. Accessed April 28, 2021. https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36
13.
GISAID. Acknowledging GISAID data contributors. Accessed July 28, 2021. https://www.gisaid.org/help/publish-with-data-from-gisaid/
14.
Centers for Disease Control and Prevention. Variant proportions. Accessed April 24, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
15.
Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. Accessed April 25, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
16.
Wagner  T, Shweta  F, Murugadoss  K,  et al.  Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis.   eLife. 2020;9:e58227. doi:10.7554/eLife.58227 PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Public Health
    November 2, 2021

    Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19

    Author Affiliations
    • 1nference, Cambridge, Massachusetts
    • 2nference Labs, Murgesh Pallya, Bengaluru, Karnataka, India
    • 3Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
    JAMA Netw Open. 2021;4(11):e2132540. doi:10.1001/jamanetworkopen.2021.32540
    Key Points

    Question  How effective is the Ad26.COV2.S adenoviral vector vaccine from Johnson & Johnson at preventing SARS-CoV-2 infection?

    Findings  This comparative effectiveness research study found that, through large-scale longitudinal retrospective curation of electronic health records from the multistate Mayo Clinic Health System, the Ad26.COV2.S vaccine had an effectiveness of 74%.

    Meaning  This study suggests that a single dose of the Ad26.COV2.S vaccine appears highly effective at preventing SARS-CoV-2 infection.

    Abstract

    Importance  Continuous assessment of the effectiveness and safety of the US Food and Drug Administration–authorized SARS-CoV-2 vaccines is critical to amplify transparency, build public trust, and ultimately improve overall health outcomes.

    Objective  To evaluate the effectiveness of the Johnson & Johnson Ad26.COV2.S vaccine for preventing SARS-CoV-2 infection.

    Design, Setting, and Participants  This comparative effectiveness research study used large-scale longitudinal curation of electronic health records from the multistate Mayo Clinic Health System (Minnesota, Arizona, Florida, Wisconsin, and Iowa) to identify vaccinated and unvaccinated adults between February 27 and July 22, 2021. The unvaccinated cohort was matched on a propensity score derived from age, sex, zip code, race, ethnicity, and previous number of SARS-CoV-2 polymerase chain reaction tests. The final study cohort consisted of 8889 patients in the vaccinated group and 88 898 unvaccinated matched patients.

    Exposure  Single dose of the Ad26.COV2.S vaccine.

    Main Outcomes and Measures  The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts, measured by SARS-CoV-2 polymerase chain reaction testing.

    Results  The study was composed of 8889 vaccinated patients (4491 men [50.5%]; mean [SD] age, 52.4 [16.9] years) and 88 898 unvaccinated patients (44 748 men [50.3%]; mean [SD] age, 51.7 [16.7] years). The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts was 0.26 (95% CI, 0.20-0.34) (60 of 8889 vaccinated patients vs 2236 of 88 898 unvaccinated individuals), which corresponds to an effectiveness of 73.6% (95% CI, 65.9%-79.9%) and a 3.73-fold reduction in SARS-CoV-2 infections.

    Conclusions and Relevance  This study’s findings are consistent with the clinical trial–reported efficacy of Ad26.COV2.S and the first retrospective analysis, suggesting that the vaccine is effective at reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirm the urgent need to continue mass vaccination efforts globally.

    ×